Concepts (100)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neuroendocrine Tumors | 5 | 2024 | 136 | 1.880 |
Why?
|
| Stomach Neoplasms | 6 | 2024 | 310 | 1.380 |
Why?
|
| Intestinal Neoplasms | 3 | 2024 | 70 | 1.190 |
Why?
|
| Pancreatic Neoplasms | 4 | 2024 | 725 | 0.930 |
Why?
|
| Receptors, Peptide | 2 | 2024 | 31 | 0.910 |
Why?
|
| X-linked Nuclear Protein | 1 | 2024 | 11 | 0.880 |
Why?
|
| Co-Repressor Proteins | 1 | 2024 | 25 | 0.870 |
Why?
|
| Molecular Chaperones | 1 | 2024 | 127 | 0.830 |
Why?
|
| Cholangiocarcinoma | 5 | 2024 | 80 | 0.820 |
Why?
|
| Bile Duct Neoplasms | 5 | 2024 | 91 | 0.810 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2024 | 684 | 0.810 |
Why?
|
| Liver Neoplasms | 6 | 2024 | 790 | 0.770 |
Why?
|
| Positron Emission Tomography Computed Tomography | 2 | 2024 | 104 | 0.770 |
Why?
|
| Carcinoma, Hepatocellular | 5 | 2024 | 426 | 0.750 |
Why?
|
| Octreotide | 3 | 2024 | 29 | 0.590 |
Why?
|
| Adenocarcinoma | 5 | 2023 | 1192 | 0.440 |
Why?
|
| Mutation | 3 | 2024 | 4374 | 0.420 |
Why?
|
| Thyroid Neoplasms | 3 | 2023 | 443 | 0.400 |
Why?
|
| Hepatectomy | 2 | 2024 | 178 | 0.390 |
Why?
|
| Appendiceal Neoplasms | 2 | 2024 | 37 | 0.360 |
Why?
|
| Embolization, Therapeutic | 2 | 2024 | 279 | 0.340 |
Why?
|
| Organometallic Compounds | 2 | 2024 | 148 | 0.240 |
Why?
|
| Aged, 80 and over | 6 | 2024 | 7215 | 0.210 |
Why?
|
| Yttrium Radioisotopes | 4 | 2024 | 48 | 0.200 |
Why?
|
| Proto-Oncogene Proteins B-raf | 2 | 2022 | 162 | 0.190 |
Why?
|
| Radioisotopes | 1 | 2022 | 43 | 0.190 |
Why?
|
| Circulating Tumor DNA | 1 | 2024 | 76 | 0.190 |
Why?
|
| Thyroid Carcinoma, Anaplastic | 1 | 2022 | 15 | 0.180 |
Why?
|
| Transplants | 1 | 2022 | 43 | 0.180 |
Why?
|
| Humans | 22 | 2024 | 95798 | 0.180 |
Why?
|
| Treatment Outcome | 9 | 2024 | 9167 | 0.170 |
Why?
|
| Aged | 9 | 2024 | 20848 | 0.170 |
Why?
|
| Esophageal Neoplasms | 2 | 2020 | 345 | 0.170 |
Why?
|
| Carcinoma, Papillary, Follicular | 1 | 2020 | 14 | 0.170 |
Why?
|
| Coordination Complexes | 1 | 2020 | 20 | 0.160 |
Why?
|
| ras Proteins | 1 | 2020 | 134 | 0.160 |
Why?
|
| Hyperthermia, Induced | 1 | 2020 | 75 | 0.160 |
Why?
|
| Middle Aged | 9 | 2024 | 28206 | 0.150 |
Why?
|
| Bile Ducts, Intrahepatic | 3 | 2023 | 68 | 0.150 |
Why?
|
| Peritoneal Neoplasms | 1 | 2020 | 187 | 0.150 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2022 | 2605 | 0.140 |
Why?
|
| Glucuronosyltransferase | 1 | 2020 | 186 | 0.140 |
Why?
|
| Retrospective Studies | 8 | 2024 | 10273 | 0.140 |
Why?
|
| Adult | 8 | 2024 | 28578 | 0.140 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2020 | 224 | 0.140 |
Why?
|
| Radiosurgery | 1 | 2021 | 316 | 0.130 |
Why?
|
| Cytoreduction Surgical Procedures | 3 | 2024 | 92 | 0.130 |
Why?
|
| Prospective Studies | 2 | 2022 | 4664 | 0.130 |
Why?
|
| Male | 9 | 2024 | 45685 | 0.120 |
Why?
|
| Liver Transplantation | 1 | 2022 | 1201 | 0.110 |
Why?
|
| Female | 9 | 2024 | 49868 | 0.110 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2020 | 1346 | 0.110 |
Why?
|
| Antibodies, Monoclonal | 1 | 2021 | 1425 | 0.110 |
Why?
|
| Transcriptome | 1 | 2020 | 770 | 0.110 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2020 | 1021 | 0.110 |
Why?
|
| Quality of Life | 1 | 2022 | 1816 | 0.100 |
Why?
|
| Combined Modality Therapy | 3 | 2022 | 1739 | 0.100 |
Why?
|
| Microspheres | 2 | 2023 | 105 | 0.100 |
Why?
|
| Radiopharmaceuticals | 2 | 2024 | 204 | 0.100 |
Why?
|
| Tumor Burden | 2 | 2024 | 322 | 0.100 |
Why?
|
| Positron-Emission Tomography | 2 | 2020 | 353 | 0.070 |
Why?
|
| Neoplasms | 1 | 2021 | 3242 | 0.060 |
Why?
|
| Time Factors | 2 | 2024 | 5561 | 0.060 |
Why?
|
| Neoplasm Staging | 2 | 2021 | 2042 | 0.060 |
Why?
|
| Hypertrophy | 1 | 2024 | 67 | 0.050 |
Why?
|
| Liver Regeneration | 1 | 2024 | 36 | 0.050 |
Why?
|
| Risk Factors | 2 | 2024 | 5961 | 0.050 |
Why?
|
| SEER Program | 1 | 2024 | 235 | 0.050 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2023 | 62 | 0.050 |
Why?
|
| Necrosis | 1 | 2023 | 210 | 0.050 |
Why?
|
| Iodine Radioisotopes | 1 | 2023 | 138 | 0.050 |
Why?
|
| Ipilimumab | 1 | 2022 | 63 | 0.050 |
Why?
|
| Capecitabine | 1 | 2022 | 99 | 0.050 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2022 | 59 | 0.040 |
Why?
|
| Pyridones | 1 | 2022 | 68 | 0.040 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2022 | 87 | 0.040 |
Why?
|
| Imidazoles | 1 | 2022 | 144 | 0.040 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2023 | 403 | 0.040 |
Why?
|
| Cisplatin | 1 | 2022 | 599 | 0.040 |
Why?
|
| Gastrectomy | 1 | 2021 | 70 | 0.040 |
Why?
|
| Response Evaluation Criteria in Solid Tumors | 1 | 2020 | 60 | 0.040 |
Why?
|
| Disease-Free Survival | 1 | 2022 | 1194 | 0.040 |
Why?
|
| DNA Repair | 1 | 2022 | 376 | 0.040 |
Why?
|
| Leucovorin | 1 | 2020 | 215 | 0.040 |
Why?
|
| Infusions, Intravenous | 1 | 2020 | 420 | 0.040 |
Why?
|
| Drug Administration Schedule | 1 | 2020 | 857 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2021 | 883 | 0.040 |
Why?
|
| Fluorouracil | 1 | 2020 | 549 | 0.040 |
Why?
|
| Molecular Targeted Therapy | 1 | 2020 | 307 | 0.030 |
Why?
|
| Obesity | 1 | 2024 | 1030 | 0.030 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2024 | 1463 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2024 | 2480 | 0.030 |
Why?
|
| Immunotherapy | 1 | 2022 | 766 | 0.030 |
Why?
|
| Infant | 1 | 2023 | 3360 | 0.030 |
Why?
|
| Survival Rate | 1 | 2020 | 1971 | 0.030 |
Why?
|
| Chicago | 1 | 2020 | 1505 | 0.030 |
Why?
|
| Genotype | 1 | 2020 | 1880 | 0.030 |
Why?
|
| Gene Expression Profiling | 1 | 2020 | 1535 | 0.030 |
Why?
|
| United States | 1 | 2024 | 7764 | 0.020 |
Why?
|
| Antineoplastic Agents | 1 | 2020 | 2385 | 0.020 |
Why?
|